Berotralstat (BCX7353): an Oral Plasma Kallikrein Inhibitor
BioCryst Kallikrein Inhibitor
oral plasma kallikrein serine protease inhibitor approved for prevention of HAE attacks from structure-based drug design berotralstat BioCryst, Birmingham, AL
Other molecules you may be interested in
remibrutinib
Remibrutinib (Novartis oral BTK-selective covalent kinase inhibitor clinical candidate)
LEO 39652
LEO 39652 (LEO Pharma “dual-soft” topical PDE4 inhibitor soft drug clinical candidate)
BI 730357
The Boehringer RORγ antagonist, BI 730357, is an oral once-daily clinical candidate from a new compound class in development for plaque psoriasis. We highlighted two other RORγ modulators last year in February and March. While most clinical RORγ modulators have discontinued development after reaching Ph. II, BI 730357’s Ph. II trial appears [...]
SHR168442
The Eternity Bioscience/Shanghai Hengrui RORγ antagonist, SHR168442, is a skin-restricted, topical compound intended to treat psoriasis. As a master regulator of Th17 immune cells which are significantly involved in allergic diseases, both positive and negative oral modulators of RORγt had been hotly pursued, though many have ceased clinical [...]
RPT193
RPT193, an oral, second-generation CCR4 inhibitor from RAPT Therapeutics, is in Ph. II clinical trials (400 mg QD) to treat atopic dermatitis (AD) (NCT05399368) and asthma (NCT05935332). CCR4 has been a long outstanding therapeutic target for treating inflammatory diseases, but despite many efforts, no molecule inhibiting this receptor has progressed beyond Ph. I for these indications.
